AUPH

MKT CAP:$2B

Aurinia Pharmaceuticals Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$16.14+$0.79 (+5.15%)

Apr 23, 2026

Company Details

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers L...

CEO

Peter S. Greenleaf

IPO Date

Sep 3, 2014

Website

www.auriniapharma.com

Key Metrics TTM

Revenue

$283M

+20.4% YoY

Net Income

$287M

EPS (Diluted)

$2.07

Free Cash Flow

$134M

Revenue / Share

$2.04

Gross Margin

88.5%

Operating Margin

37.1%

Net Margin

101.5%

FCF Margin

47.5%

P/S

7.5x

P/E

7.4x

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Feb 26, 2026

$283M+20.4%EPS $2.07

Q4 2025

Feb 26, 2026

$77M+28.8%EPS $1.53

Q3 2025

Nov 4, 2025

$73M+8.4%EPS $0.23

Q2 2025

Jul 31, 2025

$70M+22.4%EPS $0.15

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$22M	$21M	-$38M
Q2 22	$28M	$27M	-$36M
Q3 22	$56M	$53M	-$9M
Q4 22	$28M	$27M	-$28M
Q1 23	$34M	$34M	-$30M
Q2 23	$41M	$40M	-$16M
Q3 23	$55M	$48M	-$16M
Q4 23	$45M	$40M	-$30M
Q1 24	$50M	$43M	-$11M
Q2 24	$57M	$48M	-$2M
Q3 24	$68M	$62M	$12M
Q4 24	$60M	$54M	-$2M
Q1 25	$62M	$54M	$22M
Q2 25	$70M	$63M	$20M
Q3 25	$73M	$65M	$30M
Q4 25	$77M	$69M	$33M

Valuation

Quarter	P/S	P/E
Q1 22	32.1x	—
Q2 22	24.2x	—
Q3 22	16.5x	—
Q4 22	15.9x	—
Q1 23	14.5x	—
Q2 23	13.3x	—
Q3 23	13.4x	—
Q4 23	12.1x	—
Q1 24	11.1x	—
Q2 24	10.3x	—
Q3 24	9.7x	—
Q4 24	9.1x	370.2x
Q1 25	8.6x	53.4x
Q2 25	8.2x	35.1x
Q3 25	8.0x	27.4x
Q4 25	7.5x	7.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$47M	-$47M
Q2 22	-$28M	-$28M
Q3 22	-$15M	-$15M
Q4 22	$10M	$10M
Q1 23	-$32M	-$32M
Q2 23	-$3M	-$3M
Q3 23	-$13M	-$13M
Q4 23	$14M	$14M
Q1 24	-$19M	-$19M
Q2 24	$16M	$16M
Q3 24	$17M	$17M
Q4 24	$30M	$30M
Q1 25	$1M	$1M
Q2 25	$44M	$44M
Q3 25	$44M	$44M
Q4 25	$45M	$45M

Capital Expenditures

Quarter	CapEx
Q1 22	$79.0K
Q2 22	$39.0K
Q3 22	$37.7K
Q4 22	$134.0K
Q1 23	$509.0K
Q2 23	$227.0K
Q3 23	$105.0K
Q4 23	$59.0K
Q1 24	$12.0K
Q2 24	$128.0K
Q3 24	$85.0K
Q4 24	$56.0K
Q1 25	$17.0K
Q2 25	$98.0K
Q3 25	$65.0K
Q4 25	$69.8K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+2266.0%	+15.6%
Q2 22	+325.8%	+19.4%
Q3 22	+280.3%	+0.4%
Q4 22	+21.5%	+0.8%
Q1 23	+59.1%	+7.5%
Q2 23	+47.2%	-10.2%
Q3 23	-2.3%	+8.4%
Q4 23	+58.6%	+32.3%
Q1 24	+46.2%	-4.7%
Q2 24	+37.8%	+1.8%
Q3 24	+24.3%	-20.8%
Q4 24	+32.8%	-17.7%
Q1 25	+24.2%	-33.4%
Q2 25	+22.4%	-15.0%
Q3 25	+8.4%	-22.0%
Q4 25	+28.8%	-28.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$7M	32.5%
Q2 22	$10M	35.7%
Q3 22	$8M	14.9%
Q4 22	$7M	24.3%
Q1 23	$9M	27.5%
Q2 23	$12M	29.6%
Q3 23	$12M	21.7%
Q4 23	$12M	26.1%
Q1 24	$6M	11.4%
Q2 24	$9M	15.0%
Q3 24	$8M	12.3%
Q4 24	$9M	14.9%
Q1 25	-$3M	-5.5%
Q2 25	$5M	7.8%
Q3 25	$6M	8.1%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$13M	$45M	—	—
Q2 22	$12M	$52M	—	—
Q3 22	$11M	$52M	—	—
Q4 22	$10M	$47M	—	—
Q1 23	$13M	$50M	—	—
Q2 23	$13M	$44M	—	—
Q3 23	$14M	$48M	—	—
Q4 23	$10M	$50M	—	—
Q1 24	$6M	$45M	$3M	—
Q2 24	$4M	$41M	$4M	—
Q3 24	$3M	$40M	—	—
Q4 24	$8M	$31M	$14M	—
Q1 25	$6M	$19M	$970.0K	—
Q2 25	$7M	$25M	$848.0K	—
Q3 25	$8M	—	—	$26M
Q4 25	$11M	—	—	$29M

Revenue Segments

Quarter	License	Product	License, Royalty and Collaboration Revenue	License, Collaboration and Royalty Revenue
Q1 22	$133.0K	$21M	—	—
Q2 22	$43.0K	$28M	—	—
Q3 22	$30M	$26M	—	—
Q4 22	$109.0K	$28M	—	—
Q1 23	—	$34M	$72.0K	—
Q2 23	—	$41M	$394.0K	—
Q3 23	—	$41M	$14M	—
Q1 24	—	$48M	$2M	—
Q2 24	—	$55M	$2M	—
Q3 24	—	$56M	$12M	—
Q4 24	—	$58M	—	—
Q1 25	—	$60M	—	$2M
Q2 25	—	$67M	—	$3M
Q3 25	—	$71M	—	$3M
Q4 25	—	$74M	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$133M	$286M	$419M
Q2 22	$152M	$240M	$392M
Q3 22	$86M	$291M	$377M
Q4 22	$94M	$295M	$389M
Q1 23	$89M	$273M	$362M
Q2 23	$82M	$269M	$351M
Q3 23	$46M	$292M	$338M
Q4 23	$49M	$302M	$350M
Q1 24	$64M	$255M	$320M
Q2 24	$33M	$297M	$330M
Q3 24	$37M	$312M	$349M
Q4 24	$83M	$275M	$358M
Q1 25	$66M	$246M	$313M
Q2 25	$53M	$262M	$315M
Q3 25	$73M	$279M	$352M
Q4 25	$80M	$318M	$398M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	142M	+7.3%	+11.2%
Q2 22	142M	+0.0%	+10.5%
Q3 22	142M	+0.1%	+10.4%
Q4 22	142M	+0.3%	+7.7%
Q1 23	143M	+0.3%	+0.7%
Q2 23	143M	+0.1%	+0.7%
Q3 23	143M	+0.0%	+0.7%
Q4 23	144M	+0.5%	+1.0%
Q1 24	144M	+0.3%	+1.0%
Q2 24	144M	+0.1%	+0.9%
Q3 24	146M	+1.1%	+2.0%
Q4 24	148M	+1.4%	+2.8%
Q1 25	139M	-5.9%	-3.5%
Q2 25	143M	+3.1%	-0.6%
Q3 25	136M	-5.0%	-6.6%
Q4 25	139M	+2.0%	-6.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$72.1K	300
Q2 22	$94.0K	300
Q3 22	$185.9K	300
Q4 22	$94.8K	300
Q1 23	$114.7K	300
Q2 23	$138.3K	300
Q3 23	$181.7K	300
Q4 23	$150.3K	300
Q1 24	$167.7K	300
Q2 24	$190.6K	300
Q3 24	$225.9K	300
Q4 24	$460.5K	130
Q1 25	$480.5K	130
Q2 25	$538.5K	130
Q3 25	$565.1K	130
Q4 25	$386	200K

Revenue / Employee